{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-029040","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.341290+00:00","generated_at":"2026-05-26T02:10:39.175337+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Crinetics reports FY2024 net loss $298.4M; cash $1.4B; paltusotine PDUFA Sept 25, 2025","bullets":["Net loss Q4 2024: $80.6M vs $60.1M YoY; full year $298.4M vs $214.5M.","Revenue fell to $1.0M in 2024 from $4.0M in 2023; no Q4 revenue.","Cash $1.4B at Dec 31, 2024, up from $558.6M; includes $925M in equity financings.","PDUFA target action date for paltusotine (acromegaly) set for Sept 25, 2025.","Plan to start Phase 3 paltusotine in carcinoid syndrome Q2 2025 and four IND filings in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-029040","json":"https://secwatch.observer/filing/0000950170-25-029040.json","markdown":"https://secwatch.observer/filing/0000950170-25-029040.md","text":"https://secwatch.observer/filing/0000950170-25-029040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025029040/0000950170-25-029040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025029040/crnx-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:10:39.175337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}